Skip Navigation
Contact Us
Search:
Search Toggle
EN
中
Toggle Navigation
Search:
Search Submit
ABOUT US
Our Company
Our Team
expertise
Pipeline
Pipeline
FWD1509
FWD1802
News
Careers
Join Our Team
Job Opportunities
NEWS
Scroll Down
In January, FWD1509, a self-developed targeted innovative drug for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon20 insertion mutations, was approved by the US FDA for clinical trial application (IND);